Article citationsMore>>

Howard, J.F., Bril, V., Vu, T., Karam, C., Peric, S., Margania, T., et al. (2021) Safety, Efficacy, and Tolerability of Efgartigimod in Patients with Generalised Myasthenia Gravis (ADAPT): A Multicentre, Randomised, Placebo-Controlled, Phase 3 Trial. The Lancet Neurology, 20, 526-536.
https://doi.org/10.1016/s1474-4422(21)00159-9

has been cited by the following article:

• TITLE: Young-Onset Autoimmune Myasthenia Gravis in a Resource-Limited Setting: A Clinical Case Report

  AUTHORS: Cheick Ousmane Soumah, Mohamed Tafsir Diallo, Mohamed Lamine Touré, Souleymane Djigué Barry, Fodé Abass Cissé

  KEYWORDS: Myasthenia Gravis, Autoimmune Disease, Electromyography, Corticosteroids, Low-Resource Settings, Case Report

  JOURNAL NAME: Open Access Library Journal, Vol.13 No.2, February 9, 2026

  ABSTRACT: Autoimmune Myasthenia Gravis (MG) is rarely reported from low-resource settings, where diagnostic delays and limited therapeutic options remain major challenges. We report a young adult with progressive, fluctuating muscle weakness evolving over three years before diagnosis. In the absence of antibody testing and thoracic imaging, the diagnosis relied on clinical features and electrophysiological confirmation through a reproducible decrement on repetitive nerve stimulation. Corticosteroid therapy resulted in significant clinical improvement despite limited access to pyridostigmine and immunosuppressive agents. This report emphasizes the feasibility of diagnosing and managing myasthenia gravis based primarily on clinical expertise and electrophysiological testing in resource-constrained environments, and underscores the need for strengthened diagnostic capacity and access to essential medications.